Pharmaceutical Industry discussion, review, analysis, news and information.

Emergent BioSolutions, Inc. has been awarded two grants from the National Institute of Allergy and Infectious Diseases (NIAID) totaling $3.8 million to support the development of the company's anthrax immune globulin (AIG) therapeutic product.

Emergent BioSolutions, Inc. is developing its AIG product as a single dose intravenous therapeutic for post exposure treatment of patients with manifest symptoms of anthrax disease resulting from the release of anthrax toxins into the body.

Once approved, Emergent BioSolutions, Inc.’s AIG product will be prescribed for administration under these circumstances either as a monotherapy or in conjunction with antibiotics.

Read more at Emergent BioSolutions, Inc. (a pdf file)